These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22124628)

  • 1. Statins in acute coronary syndromes.
    Sposito AR; Aguiar Filho GB; Aarão AR; Sousa FT; Bertolami MC
    Arq Bras Cardiol; 2011 Oct; 97(4):350-6. PubMed ID: 22124628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive interventions in myocardial infarction: the role of statin therapy.
    Jones PH; Farmer JA
    Curr Atheroscler Rep; 2008 Apr; 10(2):142-8. PubMed ID: 18417069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: The role of statins in reducing perioperative cardiac risk: Physiologic and clinical perspectives.
    Boushra NN; Muntazar M
    Can J Anaesth; 2006 Nov; 53(11):1126-47. PubMed ID: 17079641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering agents. How important are they in secondary prevention of coronary heart disease?
    Colquhoun DM
    Aust Fam Physician; 2002 Jan; 31(1):25-6, 29-30. PubMed ID: 11840884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid management after acute coronary syndrome.
    Schwartz GG
    Curr Opin Lipidol; 2007 Dec; 18(6):626-32. PubMed ID: 17993807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the efficacy of statin treatment in acute coronary syndromes.
    Rosa GM; Carbone F; Parodi A; Massimelli EA; Brunelli C; Mach F; Vuilleumier N; Montecucco F
    Eur J Clin Invest; 2014 May; 44(5):501-15. PubMed ID: 24601937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
    Waters DD; Azar RR
    Am J Cardiol; 2000 Oct; 86(8B):35J-42J; discussion 42J-43J. PubMed ID: 11081447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions.
    Sexton T; Wallace EL; Smyth SS
    Curr Cardiol Rev; 2016; 12(4):324-329. PubMed ID: 27142048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
    Krysiak R; Okopień B; Herman Z
    Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins in acute coronary syndromes.
    Reinhardt SC; Vaughan CJ
    Drugs Today (Barc); 2002 May; 38(5):339-50. PubMed ID: 12532169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J
    Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of hypercholesterolemia in patients with acute coronary syndrome: current mechanisms and future perspectives].
    Lettino M
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):31S-7. PubMed ID: 27312021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.